Human copper transporter 1 (CTR1) has been proven to be overexpressed in many types of cancer cells, and copper (II)-64 chloride (64CuCl2) has been used as an effective tracer for positron emission tomography (PET) imaging in tumor-bearing animal models. Thus, this study aimed to investigate the potential application of 64CuCl2 in PET imaging of lung cancer through targeting CTR1.
The expression of CTR1 in a series of lung cancer cell lines was identified by quantitative real-time polymerase chain reaction (Q-PCR), western blot, enzyme-linked immunosorbnent assay (ELISA), and immunofluorescent staining. Then in vitro cell uptake assay of 64CuCl2 was investigated in human lung cancer cell lines with different levels of CTR1 expression. Small animal PET imaging and quantitative analysis were performed in human lung cancer tumor-bearing mice after intravenous injection of 64CuCl2, respectively.
The CTR1 expression in multiple human lung cancer cells was identified and confirmed, and H1299 cell lines with high CTR1 expression, H460 with moderate CTR1, and H1703 with low CTR1 were selected for further experiments. In vitro cellular uptake assay displayed that the 64CuCl2 uptake by these three kinds of cells was positively correlated with their CTR1 expressed levels. The blocking experiments testified the specificity of 64CuCl2 to target CTR1. Moreover, small animal PET imaging and quantitative results showed that 64CuCl2 accumulation in H1299, H460, and H1703 tumor-bearing mice were consistent with CTR1 levels and cell uptake experiments.
The expression of CTR1 in human lung cancer xenograft model could be successfully visualized by 64CuCl2 PET examination. With the expected growth of PET/CT examination to be an essential strategy in clinical lung cancer management, 64CuCl2 has the potential to be a promising PET imaging agent of lung cancer.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Cancer Stat Facts: Lung and Bronchus Cancer. 2020. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed Feb 2020.
Gutfilen B, Al Souza S, Valentini G. Copper-64: a real theranostic agent. Drug Des Dev Ther. 2018;12:3235–45.
Jiang L, Song D, Chen H, Zhang A, Wang H, Cheng Z. Pilot study of (64)CuCl(2) for PET imaging of inflammation. Molecules. 2018;23(2):502.
Niccoli Asabella A, Cascini GL, Altini C, Paparella D, Notaristefano A, Rubini G. The copper radioisotopes: a systematic review with special interest to 64Cu. Biomed Res Int. 2014;2014:786463.
Jiang L, Tu Y, Hu X, Bao A, Chen H, Ma X, et al. Pilot study of (64)Cu(I) for PET imaging of melanoma. Sci Rep. 2017;7(1):2574.
Kim KI, Jang SJ, Park JH, Lee YJ, Lee TS, Woo KS, et al. Detection of increased Cu-64 uptake by human copper transporter 1 gene overexpression using PET with (CuCl2)-Cu-64 in human breast cancer xenograft model. J Nucl Med. 2014;55(10):1692–8.
Righi S, Ugolini M, Bottoni G, Puntoni M, Iacozzi M, Paparo F, et al. Biokinetic and dosimetric aspects of (64)CuCl2 in human prostate cancer: possible theranostic implications. EJNMMI Res. 2018;8(1):18.
Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23(8):957–80.
Ahmedova A, Todorov B, Burdzhiev N, Goze C. Copper radiopharmaceuticals for theranostic applications. Eur J Med Chem. 2018;157:1406–25.
Follacchio GA, De Feo MS, De Vincentis G, Monteleone F, Liberatore M. Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm. 2018;11(1):22–33.
Boschi A, Martini P, Janevik-Ivanovska E, Duatti A. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. Drug Discov Today. 2018;23(8):1489–501.
Chakravarty R, Chakraborty S, Dash A. Cu-64(2+) ions as PET probe: an emerging paradigm in molecular imaging of cancer. Mol Pharm. 2016;13(11):3601–12.
Peng FY, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of (CuCl2)-Cu-64. J Nucl Med. 2006;47(10):1649–52.
Qin CX, Liu HG, Chen K, Hu X, Ma XW, Lan XL, et al. Theranostics of malignant melanoma with (CuCl2)-Cu-64. J Nucl Med. 2014;55(5):812–7.
Peng FY, Liu JG, Wu JS, Lu X, Muzik O. Mouse extrahepatic hepatoma detected on MicroPET using copper(II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imag Biol. 2005;7(5):325–9.
Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13(4):601–9.
Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18(3):765–72.
Ferrari C, Asabella AN, Villano C, Giacobbi B, Coccetti D, Panichelli P, et al. Copper-64 dichloride as theranostic agent for glioblastoma multiforme: a preclinical study. Biomed Res Int. 2015;2015:129764.
Zhang HY, Cai HW, Lu X, Muzik O, Peng FY. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol. 2011;18(12):1561–8.
Avila-Rodriguez MA, Rios C, Carrasco-Hernandez J, Manrique-Arias JC, Martinez-Hernandez R, Garcia-Perez FO, et al. Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res. 2017;7(1):98.
Panichelli P, Villano C, Cistaro A, Bruno A, Barbato F, Piccardo A, et al. Imaging of brain tumors with copper-64 chloride: early experience and results. Cancer Biother Radiopharm. 2016;31(5):159–67.
Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L, et al. (CuCl2)-Cu-64 PET/CT in prostate cancer relapse. J Nucl Med. 2018;59(3):444–51.
Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, et al. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014;85(1):88–93.
Xu X, Duan L, Zhou B, Ma R, Zhou H, Liu Z. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol. 2012;39(9):786–92.
Yoshida H, Teramae M, Yamauchi M, Fukuda T, Yasui T, Sumi T, et al. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer. Anticancer Res. 2013;33(4):1409–14.
Yu WK, Wang Z, Fong CC, Liu D, Yip TC, Au SK, et al. Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage. Br J Pharmacol. 2017;174(4):302–13.
Ceci F, Fendler W, Eiber M. A new type of prostate cancer imaging: will (64)CuCl2 PET/CT flourish or vanish? J Nucl Med. 2018;59(3):442–3.
This work was partially supported by funds from the National Natural Science Foundation of China (81971645 and 81571703), Outstanding Young Talents Program of Shanghai Municipal Commission of Health and Family Planning (2017YQ027), and Major Grant of Research and Development Program of Hunan Province of China (2019SK2252).
Conflict of interest
The authors declare no competing financial interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wang, Q., Song, D., Ma, X. et al. Preclinical PET imaging study of lung cancer with 64CuCl2. Ann Nucl Med (2020). https://doi.org/10.1007/s12149-020-01491-6
- Human copper transporter 1 (CTR1)
- Lung cancer